Bayer的新药Elinzanetant在FDA的审查中显示,在减少患乳腺癌妇女的更年期症状方面很有希望。 Bayer's new drug elinzanetant shows promise in reducing menopause symptoms in women with breast cancer, under FDA review.

拜耳的实验药物elinzanetant在乳腺癌患者中显著减少了发热和夜间出汗, 符合所有主要和次要研究目标. Bayer’s experimental drug, elinzanetant, has shown significant reductions in hot flashes and night sweats in women with breast cancer, meeting all primary and secondary study goals. ASAIS 4第3阶段的试验也发现睡眠质量和总体生活质量有所改善。 The phase 3 OASIS 4 trial also found improvements in sleep quality and overall quality of life. 该药物通过阻止某些受体发挥作用,目前正在接受林业发展局的审查,以治疗与更年期有关的症状,可以为乳腺癌患者提供一种非临床选择。 The drug, which works by blocking certain receptors, is now under FDA review for treating menopause-related symptoms and could offer a non-hormonal option for breast cancer patients.